CardioTech

CardioTech (卡尤迪) is a molecular diagnostics company that FreeS Fund (峰瑞资本) has backed since at least 2019, positioning it within the IVD and biotechnology segment of the firm's healthcare portfolio . The company specializes in point-of-care rapid molecular diagnostics, and in January 2020 it developed a nucleic acid extraction-free RNA detection kit for SARS-CoV-2 capable of one-minute sample processing, which it later exported overseas after deployment in Hubei's pandemic response . Founder Li Xiang (李响) was named to *Fortune* (Chinese edition)'s "40 Under 40" business elite list in 2020 . FreeS Fund has consistently grouped CardioTech alongside other portfolio companies such as Singleron (新格元) and XtalPi (晶泰科技) in its biomedical investment updates through 2021 . elsewhere's corpus does not contain more recent operational or financial details beyond this period.